Amie Scott

Ms. Amie Scott

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ASAmie Scott
Amie Scott
WAWajeeha Ansari
Wajeeha Ansari
FKFarid Khan
Farid Khan
RCRichard Chambers
Richard Chambers
MBMichael Benigno
Michael Benigno
JAJessica E. Atwell
Jessica E. Atwell
Background: Post-COVID conditions encompass a range of long-term symptoms after SARS-CoV-2 infection. The potential clinical and economic burden in the United States is unclear. We evaluated diagnoses, medications, healthcare use, and medical costs before and after acute COVID-19 illness in US patients at high risk of severe COVID-19. Methods: Eligible adults were diagnosed with COVID-19 from April 1 to May 31, 2020, had ≥ 1 condition placing them at risk of severe COVID-19, and were enrolled in Optum’s de-identified Clinformatics® Data Mart Database for ≥ 12 months before and ≥ 13 months after COVID-19 diagnosis. Percentages of diagnoses, medications, resource use, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified by age and COVID-19 severity. Results: The cohort included 19,558 patients (aged 18–64 y, n = 9381; aged ≥ 65 y, n = 10,177). Compared with baseline, patients during the post-acute phase had increased percentages of blood disorders (16.3%), nervous system disorders (11.1%), and mental and behavioral disorders (7.7%), along with increases in related prescriptions. Overall, there were substantial increases in inpatient and outpatient healthcare utilization, along with a 23.0% increase in medical costs. Changes were greatest among older patients and those admitted to the intensive care unit for acute COVID-19 but were also observed in younger patients and those who did not require COVID-19 hospitalization. Conclusions: There is a significant clinical and economic burden of post-COVID conditions among US individuals at high risk for severe COVID-19.

2 February 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ASAmie Scott
Amie Scott
WAWajeeha Ansari
Wajeeha Ansari
RCRichard Chambers
Richard Chambers
MRMaya Reimbaeva
Maya Reimbaeva
TMTomasz Mikolajczyk
Tomasz Mikolajczyk
JAJoanna Atkinson
Joanna Atkinson
Background: Patients recovering from SARS-CoV-2 infection and acute COVID-19 illness can experience a range of long-term post-acute effects. The potential clinical and economic burden of these outcomes in the USA is unclear. We evaluated diagnoses, medications, healthcare utilization, and medical costs before and after acute COVID-19 illness in US patients who were not at high risk of severe COVID-19. Methods: This study included eligible adults who were diagnosed with COVID-19 from April 1 to May 31, 2020, who were 18 − 64 years of age, and enrolled within Optum’s de-identified Clinformatics® Data Mart Database for 12 months before and 13 months after COVID-19 diagnosis. Patients with any condition or risk factor placing them at high risk of progression to severe COVID-19 were excluded. Percentages of diagnoses, medications, healthcare utilization, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified into 3 cohorts according to disposition during acute COVID-19 illness (i.e., not hospitalized, hospitalized without intensive care unit [ICU] admission, or admitted to the ICU). Results: The study included 3792 patients; 56.5% of patients were men, 44% were White, and 94% did not require hospitalization. Compared with baseline, patients during the post-acute phase had percentage increases in the diagnosis of the following disorders: blood (166%), endocrine and metabolic (123%), nervous system (115%), digestive system (76%), and mental and behavioral (75%), along with increases in related prescriptions. Substantial increases in all measures of healthcare utilization were observed among all 3 cohorts. Total medical costs increased by 178% during the post-acute phase. Those who were hospitalized with or without ICU admission during the acute phase had the greatest increases in comorbidities and healthcare resource utilization. However, the burden was apparent across all cohorts. Conclusions: As evidenced by resource use in the post-acute phase, COVID-19 places a significant long-term clinical and economic burden among US individuals, even among patients whose acute infection did not merit hospitalization.

17 February 2022 in Journal of Medical Economics
Verified
Journal Article
Open access
ASAmie Scott
Amie Scott
RCRichard Chambers
Richard Chambers
MRMaya Reimbaeva
Maya Reimbaeva
JAJessica Atwell
Jessica Atwell
NBNathalie Baillon-Plot
Nathalie Baillon-Plot
MTMiriam Tarallo
Miriam Tarallo
This retrospective analysis of Optum Clinformatics® Data Mart database evaluated US patient characteristics, healthcare resource utilization (HCRU), costs, and treatment patterns among unvaccinated...

31 July 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
WAWajeeha Ansari
Wajeeha Ansari
HCHenriette Coetzer
Henriette Coetzer
KGKelly A Gebo
Kelly A Gebo
JRJinma Ren
Jinma Ren
ASAmie Scott
Amie Scott
HLHeidi Leister-Tebbe
Heidi Leister-Tebbe
Background: Nirmatrelvir/ritonavir (NMV/r) is an antiviral treatment for COVID-19. We describe patient-reported outcomes with NMV/r in nonhospitalized adults with COVID-19 at high risk of severe disease. Methods: In a phase 2/3 double-blind study, high-risk adults with SARS-CoV-2 and ≤5 days of symptoms were randomized 1:1 to receive NMV/r or placebo twice daily for 5 days. Patients recorded responses to 3 Global Impression Questions (GIQs) daily through day 28 to assess return to usual health, return to usual activities, and overall severity of COVID-19-related symptoms. The COVID-19-specific Work Productivity and Activity Impairment Questionnaire (WPAI-COVID-19) and EuroQol Quality of Life 5-dimension 5-level scale (EQ-5D-5L) were completed at specified visits through week 24. Results: Compared with placebo, patients receiving NMV/r had a significant 3-day reduction in median time to return to usual health (hazard ratio [HR], 1.3; 95% confidence interval [CI], 1.2‒1.4; P < .0001), 1-day reduction in median time to return to usual activities (HR, 1.2; 95% CI, 1.1‒1.4; P < .0001), and significantly shorter GIQ times to sustained resolution of any overall symptoms (HR, 1.2; 95% CI, 1.1‒1.3; P = .0002) and sustained alleviation of any overall symptoms (HR, 1.2; 95% CI, 1.1‒1.3; P < .0001). There were no significant differences between treatment groups in the WPAI-COVID-19 or EQ-5D-5L results. Conclusions: Patients receiving NMV/r for COVID-19 reported a reduced duration and severity of COVID-19 symptoms based on their global impression of overall symptom burden and quicker return to usual health and usual activities compared with those receiving placebo. Clinical Trial Information: ClinicalTrials.gov, NCT04960202, https://clinicaltrials.gov/study/NCT04960202

1 December 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ILIngrid Lindberg
Ingrid Lindberg
KGKirk Geale
Kirk Geale
MLMathias Lilja
Mathias Lilja
CRCraig Richardson
Craig Richardson
ASAmie Scott
Amie Scott
HTHaijun Tian
Haijun Tian

1 April 2020 in Rheumatology
Verified
Journal Article
Open access
PDF file
CMChristopher L. I Morgan
Christopher L. I Morgan
AWAbigail White
Abigail White
MTMark Tomlinson
Mark Tomlinson
ASAmie Scott
Amie Scott
HTHaijun Tian
Haijun Tian
This study characterises mortality for patients with axial spondyloarthritis (axSpA) and compares mortality rates with a matched, non-axSpA population. The Clinical Practice Research Datalink, a large routine primary care database in the UK, was used to conduct this study. Patients with an incident diagnosis of axSpA from 2003-2017 were identified and matched to non-axSpA patients according to age, sex, primary care practice and concurrent practice registration. The date of first axSpA diagnosis defined the index date, and patients were followed up until death or censored at the end of follow up. Crude mortality rates were calculated and time to death from index date was analysed using the Kaplan-Meier estimator. For patients from primary care practices linked to the Office of National Statistics (ONS), cause-specific unadjusted rate ratios are presented. Two adjusted Cox proportional hazard models were conducted: 1) to assess relative mortality between axSpA patients and non-axSpA controls; and 2) to assess disease-specific factors associated with mortality for the axSpA population only. Only patients whose record could be potentially linked to ONS mortality data were included in the cause of death analysis. 4,136 incident axSpA cases were identified and matched to non-axSpA controls. Crude mortality rates were 18.9 and 11.5 per 1,000 patient-years, respectively. The most common causes of death in the axSpA cohort were coronary heart disease, cerebrovascular disease and malignant neoplasm of the bronchus and lung (Table 1). For all-cause mortality, there was a significantly increased hazard ratio (HR) of 1.531 (95% confidence interval [CI] 1.291-1.816; P < 0.001) for axSpA vs non-axSpA patients. Age (HR 1.083 [95% CI: 1.074-1.093]; P < 0.001), history of infection (HR 1.358 [95% CI: 1.082-1.705]; P = 0.008), Charlson Comorbidity Index (HR 1.194 [95% CI: 1.137-1.253]; P < 0.001) and current smoker status (HR 1.853 [95% CI: 1.396-2.461]; P < 0.001) were all significantly associated with time to death. In this study, we have shown that the presence of axSpA is associated with increased mortality compared with controls. Prior infection, comorbidity and current smoker status were associated with the greatest increased risk of mortality in patients with axSpA. Table: Most frequent causes of death and associated relative risk for axSpA and non-axSpA patients Defined as malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue. axSpA, axial spondyloarthritis; CI, confidence interval; COPD, chronic obstructive pulmonary disease; pky, 1,000 patient-years. Table: Most frequent causes of death and associated relative risk for axSpA and non-axSpA patients Defined as malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue. axSpA, axial spondyloarthritis; CI, confidence interval; COPD, chronic obstructive pulmonary disease; pky, 1,000 patient-years. C.L.I. Morgan: Other; Employee of: Pharmatelligence. A. White: Shareholder/stock ownership; Novartis. Other; Employee of: Novartis. M. Tomlinson: Consultancies; Novartis. A. Scott: Consultancies; Novartis. H. Tian: Other; Employee of: Novartis.